Posted on November 20, 2009 by Sitemaster
D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men with other “comorbid” health problems. … READ MORE …
Filed under: Management, Treatment | Tagged: comorbidity, PSA doubling time, PSA velocity, PSADT, recurrence | Leave a comment »
Posted on September 18, 2009 by Sitemaster
In today’s news reports we have focused primarily on data showing that specific things do not seem to work well in prostate cancer risk assessment and diagnosis:
- Neither PSA velocity nor the PSA/serum testosterone ratio are normally predictive for risk of prostate cancer in undiagnosed patients.
- Post-surgical tumor volume is not predictive for risk of prostate cancer progression.
- A new nomogram predicts risk of pathological upgrading post-surgery. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: free PSA, PSA, PSA velocity, PSAV, ratio, testosterone | 1 Comment »
Posted on April 23, 2009 by Sitemaster
We have reported separately on a study of the long-term durability of erectile function following brachytherapy using permanent seed implantation. Other reports today address:
- Literacy levels and prostate cancer communication
- Antiperspirant use as a possible cause of prostate (and breast) cancer
- A gene-based tool to predict prostate cancer risk
- Drugs in development for prostate cancer prevention
- PSA velocity and prostate cancer diagnosis
- Identification of good candidates for salvage radical prostatectomy … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: allele, antiperspirant, biochemical recurrence, cause, communication, Diagnosis, Literacy, Prevention, PSA velocity, risk, salvage radical prostatectomy, tool | Leave a comment »
Posted on March 23, 2009 by Sitemaster
PSA velocity is, at present, included in National Comprehensive Cancer Network guidelines as a potential prognostic factor for need for a prostate biopsy. However, Vickers and colleagues argue that calculation of PSA velocity adds nothing to the ability to predict risk for a diagnosis of prostate cancer on biopsy by comparison with simpler PSA data. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PSA velocity, risk | Leave a comment »
Posted on January 21, 2009 by Sitemaster
Today’s news includes information on:
- The use of markers for prognosis following first-line treatment for localized prostate cancer
- Results of a Phase II trial of neoadjuvant docetaxel + gefitinib prior to radical prostatectomy
- Results of a Phase III trial of gabapentin in management of ADT-related “hot flashes”
- MRI-directed HIFU in the treatment of localized prostate cancer … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: docetaxel, doubling time, gabapentin, gefitinib, HIFU, hot flashes, PSA velocity | Leave a comment »
Posted on January 3, 2009 by Sitemaster
There has been an on-going difference of opinion within sections of the urology community regarding the value of PSA velocity and/or PSA doubling times in predicting outcomes to first-line prostate cancer treatment. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: PSA doubling time, PSA velocity, risk | 2 Comments »
Posted on November 29, 2008 by Sitemaster
We have separately addressed a report on 10-year outcome data following (non-robotic) laparoscopic radical prostatectomy for localized prostate cancer. In today’s other reports we have addressed:
- The potential of annexin A3 as a marker for early diagnosis of prostate cancer
- The ability of PSAV and PSAD to predict risk for prostate cancer in men with one or more negative prostate biopsies
- Estrogens, estrogen receptors, and prostate cancer development and progression
- Differences between clinical and pathological Gleason scores and the impact on outcomes following surgery … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: annexin, estogen, Gleason score, marker, PSA density, PSA velocity, receptor | Leave a comment »
Posted on November 17, 2008 by Sitemaster
We apologize to readers the lack of a weekend news report due to travel constraints, but this report will include all the past 3 days news that we are aware of, including:
- The relative value of PSAV and PSADT in predicting risk for positive results on rebiopsy
- Prostate size and brachytherapy
- Microspcopic bladder neck invasion of prostatectomy specimens
- Early chemohormonal therapy + radiotherapy for high-risk patients … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: bladder neck invasion, chemotherapy, prostate volume, PSA doubling time, PSA velocity | Leave a comment »
Posted on October 25, 2008 by Sitemaster
Some interesting new reports today include:
- An update on the Prostate Cancer Prevention Trial
- Early data on the potential of a traditional Chinese herbal medication
- Predictive value of PSA velocity in management of low-risk patients with low-dose brachytherapy
- Reviews of emerging biomarkers and the role(s) of MRI … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Prevention | Tagged: Agaricus bazei, biomarkers, brachytherapy, finasteride, MRI, Prevention, PSA velocity | Leave a comment »
Posted on July 26, 2008 by Sitemaster
Articles summarized in this weekend news update include information about:
- The value of endorectal MRI imaging in staging patients with respect to whether they have cancer confined to the prostate or extracapsular disease
- Patterns of disease recurrence after salvage radical prostatectomy for patients with radiation-recurrent disease
- The potential of PSA kinetics to improve prediction of likelihood for survival in men with hormone-refractory prostate cancer, and
- The appropriateness of testosterone replacement therapy in men with hypogonadism after curative treatment for prostate cancer … MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cancer, endorectal, imaging, prostate, PSA, PSA velocity, replacement, salvage, staging, survival, testosterone | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 